Frontiers in Molecular Biosciences (Oct 2022)
Tackling the translational challenges of multi-omics research in the realm of European personalised medicine: A workshop report
- Emanuela Oldoni,
- Gary Saunders,
- Florence Bietrix,
- Maria Laura Garcia Bermejo,
- Anna Niehues,
- Anna Niehues,
- Peter A. C. ’t Hoen,
- Jessica Nordlund,
- Marian Hajduch,
- Andreas Scherer,
- Katja Kivinen,
- Katja Kivinen,
- Katja Kivinen,
- Esa Pitkänen,
- Esa Pitkänen,
- Esa Pitkänen,
- Tomi Pekka Mäkela,
- Tomi Pekka Mäkela,
- Ivo Gut,
- Serena Scollen,
- Łukasz Kozera,
- Manel Esteller,
- Manel Esteller,
- Manel Esteller,
- Manel Esteller,
- Leming Shi,
- Anton Ussi,
- Antonio L. Andreu,
- Alain J. van Gool
Affiliations
- Emanuela Oldoni
- European Infrastructure for Translational Medicine (EATRIS), Amsterdam, Netherlands
- Gary Saunders
- European Infrastructure for Translational Medicine (EATRIS), Amsterdam, Netherlands
- Florence Bietrix
- European Infrastructure for Translational Medicine (EATRIS), Amsterdam, Netherlands
- Maria Laura Garcia Bermejo
- Biomarkers and Therapeutic Targets Group, Ramon and Cajal Health Research Institute (IRYCIS), Madrid, Spain
- Anna Niehues
- Translational Metabolomic Laboratory, Department of Laboratory Medicine, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands
- Anna Niehues
- Center for Molecular and Biomolecular Informatics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands
- Peter A. C. ’t Hoen
- Center for Molecular and Biomolecular Informatics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands
- Jessica Nordlund
- Department of Medical Sciences, Molecular Precision Medicine and Science for Life Laboratory, Uppsala University, Uppsala, Sweden
- Marian Hajduch
- Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital in Olomouc, Olomouc, Czechia
- Andreas Scherer
- Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland
- Katja Kivinen
- Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland
- Katja Kivinen
- iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland
- Katja Kivinen
- HiLIFE-Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland
- Esa Pitkänen
- Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland
- Esa Pitkänen
- iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland
- Esa Pitkänen
- HiLIFE-Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland
- Tomi Pekka Mäkela
- iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland
- Tomi Pekka Mäkela
- HiLIFE-Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland
- Ivo Gut
- 0CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain
- Serena Scollen
- 1ELIXIR Hub, Hinxton, United Kingdom
- Łukasz Kozera
- 2Biobanking and BioMolecular Resources Research Infrastructure-European Research Infrastructure Consortium (BBMRI-ERIC), Graz, Austria
- Manel Esteller
- 3Josep Carreras Leukemia Research Institute (IJC), Badalona, Spain
- Manel Esteller
- 4Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain
- Manel Esteller
- 5Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
- Manel Esteller
- 6Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain
- Leming Shi
- 7State Key Laboratory of Genetic Engineering, School of Life Sciences and Human Phenome Institute, Fudan University, Shanghai, China
- Anton Ussi
- European Infrastructure for Translational Medicine (EATRIS), Amsterdam, Netherlands
- Antonio L. Andreu
- European Infrastructure for Translational Medicine (EATRIS), Amsterdam, Netherlands
- Alain J. van Gool
- Translational Metabolomic Laboratory, Department of Laboratory Medicine, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands
- DOI
- https://doi.org/10.3389/fmolb.2022.974799
- Journal volume & issue
-
Vol. 9
Abstract
Personalised medicine (PM) presents a great opportunity to improve the future of individualised healthcare. Recent advances in -omics technologies have led to unprecedented efforts characterising the biology and molecular mechanisms that underlie the development and progression of a wide array of complex human diseases, supporting further development of PM. This article reflects the outcome of the 2021 EATRIS-Plus Multi-omics Stakeholder Group workshop organised to 1) outline a global overview of common promises and challenges that key European stakeholders are facing in the field of multi-omics research, 2) assess the potential of new technologies, such as artificial intelligence (AI), and 3) establish an initial dialogue between key initiatives in this space. Our focus is on the alignment of agendas of European initiatives in multi-omics research and the centrality of patients in designing solutions that have the potential to advance PM in long-term healthcare strategies.
Keywords
- personalised medicine
- translational medicine
- multi-omics
- EU initiatives
- research infrastructures
- bottlenecks in health data
